Rhythm Pharmaceuticals Inc (RYTM)
40.63
-0.76
(-1.84%)
USD |
NASDAQ |
Jun 20, 16:00
40.66
+0.03
(+0.07%)
After-Hours: 20:00
Rhythm Pharmaceuticals Research and Development Expense (Annual): 134.95M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 134.95M |
| December 31, 2022 | 108.63M |
| December 31, 2021 | 104.13M |
| December 31, 2020 | 90.45M |
| December 31, 2019 | 109.45M |
| Date | Value |
|---|---|
| December 31, 2018 | 50.34M |
| December 31, 2017 | 22.89M |
| December 31, 2016 | 19.59M |
| December 31, 2015 | 7.148M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
90.45M
Minimum
2020
134.95M
Maximum
2023
109.52M
Average
108.63M
Median
2022
Research and Development Expense (Annual) Benchmarks
| Pfizer Inc | 10.68B |
| Amgen Inc | 4.784B |
| Eli Lilly and Co | 9.313B |
| Viking Therapeutics Inc | 63.81M |
| Amicus Therapeutics Inc | 152.38M |